The management and prevention of vancomycin-resistant enterococci

Infections in Medicine

Volumn 13, Issue 6, 1996, Pages 487-488+493

  Stosor, Valentina ^a   Noskin, Gary A ^a   Peterson, Lance R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug resistance; Enterococci; Vancomycin

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; NOVOBIOCIN; RIFAMPICIN; SULBACTAM; TEICOPLANIN; TROSPECTOMYCIN; VANCOMYCIN; VANCOMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS; HUMAN; INFECTION;

EID: 0029681982     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infections. Am J Med 91 (suppl 3B):S73-S75, 1991.
2. Moellering RC: Emergence of enterococcus as a significant pathogen. Clin Infect Dis 14:1173-1178, 1992.
3. Murray BE: The life and the times of the enterococcus. Clin Microbiol Rev 3:45-65, 1990.
4. Kaye D: Enterococci: Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med 142:2006-2009, 1982.
5. Maki DG, Agger WA: Enterococcal bacteremia: Clinical features, the risk of endocarditits, and management Medicine (Baltimore) 67:248-269, 1988.
6. Leclercq R, Dutka-Malen S, Brisson-Noël A, et al: Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis 15:495-501, 1992.
7. Herman DJ, Gerding DN: Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 35:1-4, 1991.
8. Zervos MJ, Schaberg DR: Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother 28:446-448, 1995.
9. Arthur M, Courvalin P: Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37:1563-1571, 1993.
10. Moellering RC: The Garrod Lecture. The enterococcus: A classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 28:1-12, 1991.
11. Shlaes DM, Binczewski B, Rice LB: Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 17 (Suppl 2):S527-S536, 1993.
12. Rhinehart E, Smith NE, Wennersten C: Rapid dissemination of beta-lactamase-producing, amino-glycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med 323:1814-1818, 1990.
13. Handwerger S, Perlman DC, Altarac D, et al: Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 14:655-666, 1992.
14. Murray BE: Beta-lacatamase-producing enterococci. Antimicrob Agents Chemother 36:2355-2359, 1992.
15. Shaberg DR, Dillon WI, Terpenning MS, et al: Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 36:2533-2535, 1992.
16. Leclercq R, Derlot E, Duval J, et al: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319:157-161, 1988.
17. Rubin LG, Tucci V, Cercenado E, et al: Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 13:700-705, 1992.
18. Karanfil LV, Murphy M, Josephson A, et al: A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 13:195-200, 1992.
19. Frieden TR, Munsiff SS, Low DE, et al: Emergence of vancomycin-resistant enterococci in New York City. Lancet 342:76-79, 1993.
20. Boyle JF, Soumakis SA, Rendo A, et al: Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 31:1280-1285, 1993.
21. Montecalvo MA, Horowitz H, Gedris C, et al: Outbreak of vancomycin-, ampicillin-, and amino-glycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 38:1363-1367, 1994.
22. Handwerger S, Raucher B, Altarac D, et al: Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 16:750-755, 1992.
23. Uttley AH, Woodford N, Johnson AP, et al: Vancomycin-resistant enterococci. Lancet 342:615, 1993.
24. Wade J, Rolando N, Casewell M: Resistance of Enterococcus faecium to vancomycin and teicoplanin. Lancet 337:1616, 1991.
25. Centers for Disease Control and Prevention: Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 42:597-599, 1993.
26. Spera RV, Farber BF: Multiply-resistant Enterococcus faecium - the nosocomial pathogen of the 1990s. JAMA 268:2563-2564, 1992.
27. Leclercq R, Derlot E, Weber M, et al: Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 33:10-15, 1989.
28. Willey BM, McGeer AJ, Ostrowski MA, et al: The use of molecular typing techniques in the epidemiologic investigation of resistant enterococci. Infect Control Hosp Epidemiol 15:548-556, 1994.
29. Quintiliani R, Evers S, Courvalin P: The vanB gene confers various levels of self-transferable resistance to vancomycinin enterococci. J Infect Dis 167:1220-1223, 1993.
30. Navarro F, Courvalin P: Analysis of genes encoding D-Alanine-D-Alanine ligase-related enzymes in Enterococcus casselifavus and Enterococcus flavescens. Antimicrob Agents Chemother 38:1788-1793, 1994.
31. Arthur M, Molinas C, Depardieu F, et al: Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 175:117-127, 1993.
32. Barna JCJ, Williams DH: The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 38:339-357, 1984.
33. Nagarajan R: Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother 35:605-609, 1991.
34. Bugg TD, Wright GD, Dutka-Malen S et al: Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30:10408-10415, 1991.
35. Arthur M, Depardieu F, Snaith HA et al: Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob Agents Chemother 38:1899-1903, 1994.
36. Arthur A, Molinas C, Courvalin P: The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 174: 2582-2591, 1992.
37. Dutka-Malen S, Molinas C, Arthur M, et al: Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene 112:53-58, 1992.
38. Evers S, Sahm DF, Courvalin P:The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide resistance proteins vanA and vanC. Gene 24:143-144, 1993.
39. Edmond MB, Ober JF, Weinbaum DL, et al: Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin Infect Dis 20:1126-1133, 1995.
40. Pallares R, Pujol M, Pena C, et al: Cephalosporins as risk factor for nosocomial Entercoccus faecalis bacteremia. A matched case-control study. Arch Intern Med 153:1581-1586, 1993.
41. Noskin GA, Till M, Patterson BK, et al: High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 164:1212-1215, 1991.
42. Noskin GA, Peterson LR, Warren JR: Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 20:296-301, 1995.
43. Livornese LL, Dias S, Samel C, et al: Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 117:112-116, 1992.
44. Pouedras P, Leclercq R, Donnio PY, et al: Bacteremia due to vancomycin-resistant Enterococcus faecium of vanB phenotype during prophylaxis with vancomycin. Clin Infect Dis 15:752-753, 1992.
45. Boyce JM, Opal SM, Chow JW, et al: Outbreak of multidrug-resistant Ebterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 32:1148-1153, 1994.
46. Guiot HF, Peetermans WE, Sehens FW: Isolation of vancomycin-resistant enterococci in haematologic patients. Eur J Clin Microbiol Infect Dis 10: 32-34, 1991.
47. Zervos MJ, Bacon AE, Patterson JE, et al: Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 21:113-115, 1988.
48. Green M, Barbadora K, Michaels M: Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol 29:2503-2506, 1991.
49. Noskin GA, Stosor V, Cooper I, et al: Recovery of vancomycin resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 16:577-581, 1995.
50. Fraimow HS, Venuti E: Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 36:1563-1566, 1992.
51. Leclercq R, Bitigen E, Su QH, et al: Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 35:92-98, 1991.
52. Nicas TI, Cole CT, Preston DA, et al: Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother 33:1477-1481, 1989.
53. Sader HS, Pfaller MA, Tenover FC, et al: Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J Clin Microbiol 32:2840-2842, 1994.
54. French P, Venuti E, Fraimow HS: In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicrob Agents Chemother 37:2736-2739, 1993.
55. Landman D, Mobaraki NK, Quale JM: Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrob Agents Chemother 37:1904-1908, 1993.
56. Unal S, Flokowitsch J, Mullen DL, et al: In-vitro synergy and mechansim of interaction between vancomycin and ciprofloxacin against enterococcal isolates. J Antimicrob Chemother31:711-723, 1993.
57. Fantin B, Leclercq R, Arthur M, et al: Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother 35:1570-1575, 1991.
58. Witman MS, Pitsakis PG, Zausner A, et al: Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 37:2069-2073, 1993.
59. Quale JM, Landman D, Mobaraki N: Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin. J Antimicrob Chemother 34:797-802, 1994.
60. Caron F, Lemeland JF, Humbert G, et al: Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin- and glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 168:681-686, 1993.
61. Caron F, Pestel M, Kitzis MD, et al: Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly glycopeptide-resistant isolate of Enterococcusfaecium. J Infect Dis 171:106-112, 1994.
62. Mekonen ET, Noskin GA, Hacek DM, et al: Successful treatment of persistent bacteremia due to vancomycin-resistant Enterococcus faecium. Microbiol Drug Resis 1:249-253, 1995.
63. Norris AH, Reilly JP, Edelstein PH, et al: Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 20:1137-1144, 1995.
64. Hospital Infection Control Practices Advisory Committee: Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16:105-113, 1995.
65. Stosor V, Noskin G, Frauchiger W, et al: Importance of washing technique on the persistence of vancomycin-resistant enterococci on hands, in Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Orlando, Fla., 1994.
66. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Publication M7-A3, ed 3. Villanova, Pa.: National Committee for Clinical Laboratory Standards, 1993.
67. Facklam RR, Collins MD: Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 27:731-734, 1989.
68. Tenover FC, Tokars J, Swenson J, et al: Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol 31:1695-1699, 1993.
69. Swenson JM, Ferrarro MJ, Sahm DF, et al: The National Committee for Clinical Laboratory Standards Working Group on Enterococci. New vancomycin disk diffusion breakpoints for enterococci. J Clin Microbiol 30:2525-2528, 1992.
70. Yamaguchi E, Valenca F, Smith S, et al: Colonization pattern of vancomycin-resistant Enterococcus faecium. Am J Infect Control 22:202-206, 1994.
71. Murray BE: Can antibiotic resistance be controlled? N Engl J Med 330:1229-1230, 1994.
72. Ena J, Dick RW, Jones RN, et al: The epidemiology of intravenous vancomycin usage in a university hospital: A 10-year study. JAMA 269:598-602, 1993.
73. Rubin M, Hathorn JW, Marshall D, et al: Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30-35, 1988.
74. Karp JE, Dick JD, Angelopulos C, et al: Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med 81:237-242, 1986.
75. Pizzo PA, Hathorn JW, Hemenez J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:555-558, 1986.
76. Maki DG, Schuma AA: Astudy of antimicrobial misuse in a university hospital. Am J Med Sci 275:271-282, 1978.
77. Johnson S, Homann SR, Bettlin KM, et al: Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 117:297-302, 1992.
78. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227-1231, 1990.
79. Durack DT: Prevention of infective endocarditis. N Engl J Med 332:3844, 1995.
80. Noskin GA, Postelnick M, Peterson LR: Control of enterococci by restriction of third generation cephalosporins, in Abstracts of the 32nd Annual Meeting of the Infectious Diseases Society of America. Clin Infect Dis 19:597, 1994.
81. Stosor V, Cooper I, Reisberg B, et al: Clonal complexity in management of vancomycin resistant enterococci, in Abstracts of the 95th General Meeting of the American Society for Microbiology. Washington, D.C.: American Society for Microbiology, 1995.
82. O'Donovan CA, Fan-Havard P, Tecson-Tumang FT, et al: Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis 18:105-109, 1994.
83. Torres C, Reguera JA, Sanmartin MJ, et al: vanA-medicated vancomycin-resistant Enterococcus spp. in sewage. J Antimicrob Chemother 33:553-561, 1994.
84. Van der Auwera P, Pensart N, Korten V, et al: Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci. J Infect Dis 173:1129-1136, 1996.